Summary
71 / 100 · Bulios Score
What speaks for it
- Revenue grew by 22% a year over the last 3 years.
- It holds more cash than debt: $19.4M against $1.69M.
- Out of every 100 CAD of revenue, 13 CAD is left as net profit.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 24.7 CAD for 1 CAD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (CAD)
Diluted EPS (CAD)
- Analyst estimate
Revenue grew by 4.9% a year over 5 years. Over the last 3 years it grew by 22% a year.
Growth in detailDoes it make money?
Very wellWhere 100 CAD of revenue goes
- Cost of sales 42 CAD
- Research and development 2.6 CAD
- Sales and administration 44 CAD
- Taxes and other -1.3 CAD
- Net profit 13 CAD
Net profit, industry median (Medical - Instruments & Supplies) 8.1 CAD
Out of every 100 CAD of revenue, 13 CAD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 3.80%
- Paid out of profit
- 94%
The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.